Molecular Formula | C23H30O3 |
Molar Mass | 354.48 |
Density | 1.0304 (rough estimate) |
Melting Point | 104-1050C |
Boling Point | 447.69°C (rough estimate) |
Flash Point | 219.4°C |
Solubility | Chloroform (Slightly), DMSO (Slightly, Sonicated), Ethyl Acetate (Slightly), Met |
Vapor Presure | 2.22E-10mmHg at 25°C |
Appearance | Crystalline solid |
Color | Light Yellow to Yellow |
Storage Condition | Sealed in dry,2-8°C |
Stability | Light Sensitive |
Refractive Index | 1.5480 (estimate) |
MDL | MFCD00866624 |
Use | For the treatment of severe psoriasis, erythematous keratosis |
In vivo study | After 28 days of treatment of mice with Etretinate, the average dermal thickness of the experimental mice was significantly reduced and the collagen bundles were changed compared with the control group. The TUNEL experiment demonstrated that the density of TUNEL-positive cells in the skin of the experimental group of mice (treated with etretinate for 14 days) increased significantly. The ratio of procollagen α 1(I) to β actin mRNA decreased significantly in mice treated with etretinate for 1 day, but increased after 14 days of treatment. Treatment of MRL/lpr mice with Etretinate reduced dermal thickness, inhibited skin damage by inducing apoptosis and regulating cytokine expression. |
HS Code | 2918992090 |
Toxicity | LD50 in mice (1 day): >4000 mg/kg i.p. (Bollag); LD50 (20 day) in mice, rats (mg/kg): 1176, >2000 i.p.; >2000, >4000 orally (Kamm) |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
Effect | Etretixate has an inhibitory effect on psoriasis and dyskeratosis. It can also inhibit lysosomal release and neutrophil chemotaxis. |
use | is effective for the treatment of chronic and refractory keratotic diseases such as psoriasis, follicle keratosis, palmoplantar keratosis and pityriasis rubra. for the treatment of severe psoriasis, erythematous keratosis, etc. |
preparation | add 15g of acetonitrile, 0.09g of palladium charcoal and 0.63g of triphenylphosphine into a 100ml beaker, and stir fully to completely dissolve triphenylphosphine. The prepared palladium-carbon composite catalyst was added to the mixture prepared according to Example 1, heated to 75 degrees C for 4h, filtered, and recovered palladium. Then 60g of potassium hydroxide solution (18g of potassium hydroxide and 42g of water medium) was added into the filtrate for 2h of heat preservation and hydrolysis reaction. After the end, the temperature is reduced to 30 ℃, the pH value is adjusted to 5.0 with glacial acetic acid, 480g of purified water is added, the temperature is increased to 60 ℃, the filter cake is pumped into a 500ml three-mouth bottle, 450g of acetone is added under stirring, the temperature is increased to 55 ℃, and the temperature is kept for 3 hours. Filter by suction and drying to obtain 17.8g of etratide with 69.3% yield and 99.5% content. |
biological activity | Etretinate (Tegison, Ethyl etrinoate, Retinoid, Etretinato) is an oral aromatic vitamin a acid, which is very effective in the treatment of fresh cowhide and other skin syndromes. It can activate retinol receptors, induce cell differentiation, inhibit cell proliferation and inhibit tissue infiltration. |
Target | Value |
toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |